Why the study?
Adverse outcomes including mortality after major gastrointestinal bleeding in patients receiving anticoagulants are not well characterized and may be underappreciated.
What is the risk of 30-day all-cause mortality after major gastrointestinal bleeding in adults receiving direct oral anticoagulants for atrial fibrillation or venous thromboembolism?
Systematic Review
What is the risk of 30-day all-cause mortality after major gastrointestinal bleeding in adults receiving direct oral anticoagulants for atrial fibrillation or venous thromboembolism?
This protocol outlines a systematic review and meta-analysis to quantify the 30-day all-cause mortality following major gastrointestinal bleeding in patients taking direct oral anticoagulants.
Mortality risk after DOAC-related major GI bleeding remains poorly quantified; this meta-analysis leaves open precise estimates and need for prospective data.
BACKGROUND: Gastrointestinal (GI) bleeding represents the single most frequent site of anticoagulant-related bleeding. Adverse outcomes after major GI bleeding including mortality are not well characterized and, as a result, may be underappreciated in clinical practice. We aim to conduct a systematic review and meta-analysis of the risk for 30-day all-cause mortality after major GI bleeding among patients receiving DOACs. METHODS: Electronic databases including MEDLINE, EMBASE, and Cochrane CENTRAL will be systematically searched to identify randomized controlled trials and prospective and retrospective cohort studies reporting 30-day all-cause mortality in adults with DOAC-related major GI bleeding. At least two investigators will independently perform study selection, risk of bias assessment, and data extraction. The proportion of deaths following a major GI event relative to the number of major GI bleeding events will be calculated for each individual study, and results across studies will be pooled using random-effects meta-analysis. We will assess risk of bias using criteria proposed by the GRADE group for prognostic studies. DISCUSSION: The findings of this systematic review and meta-analysis will provide clinicians and patients with estimates of mortality after the most common major bleeding event to support shared decision making about anticoagulation management. TRIAL REGISTRATION: PROSPERO CRD42022295815.
No takes yet. Share an insight, caveat, or question.
Chornenki et al. (2022) conducted a systematic review in Major gastrointestinal bleeding in patients receiving direct oral anticoagulants. Direct oral anticoagulants (DOACs) was evaluated on 30-day all-cause mortality after major GI bleeding. Direct oral anticoagulant-related major gastrointestinal bleeding is the focus of this systematic review protocol, which aims to determine the risk of 30-day all-cause mortality but has not yet reported clinical results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: